Search for: [Abstract = "graphic data and arterial hypertension, however overweight was more common in VTE patients. There were no differences in laboratory data between the groups at the baseline, except for higher CRP \(1.66 \[interquartile range 0.74\-2.22\] mg\/l vs 0.84 \[0.54\-1.12\] mg\/l, p= 0.03\), glucose \(5.66 ±0.36 mM vs. 5.44 ±0.36 mM, p= 0.03\) and t\-PA levels \(14.05 \[11.05\-17.35\] ng\/ml vs 10.80 \[10.10\-13.70\] ng\/ml, p= 0.015\) in VTE patients. Plasma fibrin clot variables prior to atorvastatin administration significantly differed between two groups. VTE patients displayed 9% faster protofibril formation and 14.2% thicker fibrin fiber formation, together with 27.4% lower clot permeability and 25% lysability compared to control group \(p for all <0.0001\). The presence of RVT in the lower extremity deep veins \(n=9\) led to faster protofibril \(lag phase 41.2 ±2.5 s vs 44.5 ±2.8 s, p= 0.005\) and thicker fibrin fiber \(Δ Abs 0.9 ±0.04 vs 0.8 ±0.06, p= 0.005\) formation together with lower clot permeability \(Ks 6.0 ±0.9 \*10\-9 cm2 vs 7.2 ±1.4 \*10\-9 cm2, p= 0.03\) and lysability \(t50% 10.6 \[9.5 – 11.3\] min vs 9.9 \[7.5 – 10.3\] min, p= 0.03\). In control group atorvastatin decreased total \(TC\), low\-density lipoprotein cholesterol \(LDL\-C\) and triglyceride levels \(p for all <0.05\), while CRP level remained unchanged. A reduction in CLT \(by 11%, p= 0.003\) was noted\; other fibrin parameters were unaltered. Atorvastatin in V"]

Number of results: 1